Date: 2013-08-01
Type of information: Grant
Company: ReNeuron (UK)
Investors: Technology Strategy Board (UK)
Amount: £1.5 million (€1.7 million)
Funding type: grant
Planned used: The grant will part-fund Reneuron’s Phase II clinical trial of its ReN001 stem cell therapy for disabled stroke patients. The trial is expected to commence in the UK later this year.
Others: * On August 1, 2013, ReNeuron has announced that it has been awarded a £1.5 million grant from the Technology Strategy Board (TSB), an innovation agency of the UK Government, under its Supporting Regenerative Medicines and Cell Therapies Competition. Earlier this year, ReNeuron was awarded two further grants from the TSB under its Biomedical Catalyst scheme, to part-fund its therapeutic programmes targeting critical limb ischaemia and retinitis pigmentosa. The Company is also receiving support from the Cell Therapy Catapult, an innovation centre established by the TSB, with regard to the processes used to manufacture the Company’s cell-based therapeutic candidates. ReNeuron has also recently announced a £25 million equity fundraising and £7.8 million grant package from the Welsh Government.
Therapeutic area: Regenerative medicine - Neurological diseases
